Echoiq Limited · ASX:EIQ
Echoiq — Investor Presentation (September 2021)
20 slides from Echoiq's investor presentation, Sep 7, 2021
Slide 1: ECHOiQ
ECHOiQ Using the power of artificial intelligence to reinvent cardiac diagnostics ECHOiQ I SEPTEMBER 2021
Slide 2: Disclaimer & Forward Looking Statements
Disclaimer & Forward Looking Statements This presentation has been prepared by Houston We Have “HWH”. This document contains background information about HWH current at the date of this presentation, 6 September 2021. The presentation is in summary form and does not purport to be all inclusive or co
Slide 3: ECHOiQ Company Background
ECHOiQ Company Background .............................................. Focused on the application of advanced AI and machine learning to transform cardiac-diagnostics Technology developed with expert and highly published cardiology team ECHOiQ acquired by ASX-listed Houston We Have (HWH) in June 2
Slide 4: Houston We Have: Corporate Snapshot
Houston We Have: Corporate Snapshot Capital Structure (ASX: HWH) ECHOiQ Leadership Team Share price (6 Sep 2021) $0.155 Andrew Grover Executive Chair Shares on issue 387,207,713 Prof Geoff Strange VP Global Medical and Corp Strategy Options Issued 169,550,900 Prof David Playford Chief Medical Office
Slide 5: About ECHOiQ
ECHOiQ About ECHOiQ What it is Solution Unique AI technology used to identify ECHOiQ uses echocardiographic data at-risk and treatable patients with and applies a combination of advanced structural heart disease (such as machine learning and current valvular disease and heart failure) diagnostic gui
Slide 6: ECHOiQ : The time is now
ECHOiQ ECHOiQ : The time is now Research confirms Unique access to big data Real advances in 1...................................................................................................... widespread underdiagnosis linked to mortality tech capability 2 3 Heart valve diseases are ECHOiQ holds
Slide 7: Aortic Stenosis
ECHOiQ Aortic Stenosis What it is Aortic Stenosis is a disease of calcification that causes a narrowing of the valve opening and an increase in pressure. It is the most common form of heart valve disease, but is highly treatable when diagnosed early enough. ECHOiQ I SEPTEMBER 2021
Slide 8: An evolving research picture
ECHOiQ An evolving research picture Real advances in tech capability Ross + Braunwald’s 1968 curve indicated Multiple big data sources reveal a Using advances in Big Data and that there was a long “latent” period of different picture – one that shows a computing power we actually believe AS followed
Slide 9: NEDA
ECHOiQ NEDA ECHOiQ has 17 years exclusive access to NEDA 1.0 and 2.0, the largest database of its type, linked to mortality, worldwide 1.0 2.0 3.0 4.0 IN DEVELOPMENT H1 2021 H2 2021 H2 2022 H2 2022 330,000 650,000 1,000,000 individuals 2,000,000 individuals individuals individuals > 100,000,000 250,
Slide 10: Game-Changing Data
ECHOiQ Game-Changing Data • High Gradient aortic stenosis (AS) often missed • Low Gradient AS even more often missed and with even higher mortality • A novel approach is needed Snir A, Strange, Playford D and Celermajer. JAHA 2021 in press
Slide 11: ECHOiQ
ECHOiQ ECHOiQ I SEPTEMBER 2021 ECHOiQ A novel approach to diagnosis Traditional Diagnosis The ECHOiQ Approach • Highly dependent on the frequently inaccurate • Avoids use of LVOT data and creates a risk-factor continuity equation (a view of the Left Ventricular based on AS phenotype in a novel appro
Slide 12: ECHOiQ: Understanding the impact
ECHOiQ ECHOiQ Understanding the impact Echo remains the most important and widely-used means of diagnosing heart valve disease (AS being the most prevalent form). In our most recent validation study on 300,000 people (M/F/Avg age 62) using ECHOiQ Enhanced Screening Program (ESP) protocols we saw: US
Slide 13: ECHOiQ: Changing the paradigm for patients
ECHOiQ ECHOiQ Changing the paradigm for patients The ECHOiQ Enhanced Screening Program for aortic stenosis doubles the detection of patients deemed to be at-risk, and in need of careful review by their doctor to determine the best course of management to lower their risk. This breakthrough has impor
Slide 14: Strategic Focus Clinical Study
ECHOiQ Strategic Focus Clinical Study PHASE ECHOiQ Algorithm POC developed using 1 machine learning, data science and imputation Partners: NEDA + Edwards LifeSciences Algorithm validation study on 330,000 Funding: 2 records successfully completed and published Study fully funded by Edwards LifeScien
Slide 15: Strategic Focus Clinical Study
ECHOiQ Strategic Focus Clinical Study A successful clinical trial can pave the way for regulatory success. The recently announced trial has two primary objectives. 1. To evaluate the performance of ECHOiQ’s AI based ESP technology in identifying patients with aortic stenosis in de-novo echocardiogra
Slide 16: Market Segments
ECHOiQ Market Segments Leaving no patient behind means deploying our solution across sectors and partners Hospital Groups + Valve ECHO Hardware Specialist Cardiology General Health Maintenance Manufacturers Manufacturers Community Organisations Practitioners + Software + Software + Software + Softwa
Slide 17: Market Opportunity
ECHOiQ Market Opportunity Valve Echo Machines Cardio Specialists HMOs/Hospitals General Practice Manufacturers + S/W + S/W + S/W + S/W + S/W Who? • Increased AS diagnosis • Drives added value • Enhanced accuracy • Enhanced accuracy • Knowledge access Why? • Market growth in huge services revenue • D
Slide 18: Scale of Opportunity – The Beginning
ECHOiQ Scale of Opportunity – The Beginning Half of all ECHOiQ could increase early detection of risk, opening up pathways to people with treatment. The CURRENT valve market is worth in excess of US$5bn per heart valve year, and ECHOiQ could be instrumental in unlocking significant growth in disease
Slide 19: Purpose Client Base Status
Purpose Houston We Have helps organisations make better decisions, at speed and without bias. Using AI, data science and patented software the company helps generate plausible conclusions from myriad data sources and the observations of subject matter experts. Client Base Its military grade software
Slide 20: ECHOiQ
ECHOiQ Using the power of ai to reinvent cardiac diagnostics Investor enquiries: Andrew Grover, Executive Chair / Andrew.grover@echoiq.ai investor@HoustonWeHave.ai Media enquiries: Media & Capital Partners Kristian Towse / Kris.Towse@mcpartners.com.au ECHOiQ I SEPTEMBER 2021